Wang ZT - Search Results

1

Feasibility of shrinking field radiation therapy through 18F-FDG PET/CT after 40 Gy for stage III non-small cell lung cancers.

Ding XP, Zhang J, Li BS, Li HS, Wang ZT, Yi Y, Sun HF, Wang DQ. Ding XP, et al. Among authors: wang dq, wang zt. Asian Pac J Cancer Prev. 2012;13(1):319-23. doi: 10.7314/apjcp.2012.13.1.319. Asian Pac J Cancer Prev. 2012. PMID: 22502693 Free article.

2

Phase I study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and Capecitabine, Cisplatin for locally advanced esophageal squamous cell carcinoma.

Li BS, Zhou T, Wang ZT, Li HS, Sun HF, Zhang ZC, Lin HQ, Wei YM, Gong HY, Huang W, Yi Y, Wang LY. Li BS, et al. Among authors: wang ly, wang zt. Radiother Oncol. 2009 Dec;93(3):458-61. doi: 10.1016/j.radonc.2009.08.002. Epub 2009 Sep 3. Radiother Oncol. 2009. PMID: 19733411 Clinical Trial.

3

Clinical and dosimetric risk factors of acute esophagitis in patients treated with 3-dimensional conformal radiotherapy for non-small-cell lung cancer.

Zhang ZC, Xu J, Li BS, Zhou T, Lu J, Wang ZT, Li HS, Sun HF, Zhu J, Yu JM. Zhang ZC, et al. Among authors: wang zt. Am J Clin Oncol. 2010 Jun;33(3):271-5. doi: 10.1097/COC.0b013e3181a879e0. Am J Clin Oncol. 2010. PMID: 19823071

4

CYFRA21-1 and CEA are useful markers for predicting the sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma.

Yi Y, Li B, Wang Z, Sun H, Gong H, Zhang Z. Yi Y, et al. Biomarkers. 2009 Nov;14(7):480-5. doi: 10.3109/13547500903180265. Biomarkers. 2009. PMID: 19863186

5

Predictors of sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma.

Yi Y, Li B, Sun H, Zhang Z, Gong H, Li H, Huang W, Wang Z. Yi Y, et al. Tumour Biol. 2010 Aug;31(4):333-40. doi: 10.1007/s13277-010-0041-9. Epub 2010 May 20. Tumour Biol. 2010. PMID: 20490963

6

CYFRA21-1 can predict the sensitivity to chemoradiotherapy of non-small-cell lung carcinoma.

Wang J, Yi Y, Li B, Wang Z, Sun H, Zhang P, Huang W. Wang J, et al. Biomarkers. 2010 Nov;15(7):594-601. doi: 10.3109/1354750X.2010.504308. Epub 2010 Jul 23. Biomarkers. 2010. PMID: 20649505

7

Decline of serum CYFRA21-1 during chemoradiotherapy of NSCLC: a probable predictive factor for tumor response.

Wang J, Zhang N, Li B, Wang Z, Sun H, Yi Y, Huang W. Wang J, et al. Tumour Biol. 2011 Aug;32(4):689-95. doi: 10.1007/s13277-011-0169-2. Epub 2011 Mar 16. Tumour Biol. 2011. PMID: 21409421

8

Phase I study of pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced non-small cell lung cancer.

Li BS, Gong HY, Huang W, Yi Y, Yu JM, Wang ZT, Zhang ZC, Sun HF, Li HS, Wang LY. Li BS, et al. Among authors: wang ly, wang zt. Am J Clin Oncol. 2012 Apr;35(2):115-9. doi: 10.1097/COC.0b013e318209ab93. Am J Clin Oncol. 2012. PMID: 21555933 Clinical Trial.

9

Serum superoxide dismutase, a potential predictor for radiation pneumonitis following chemoradiotherapy in non-small cell lung cancer patients.

Wang D, Zhu J, Sun M, Li B, Wei L, Wang Z, Sun H. Wang D, et al. Biomarkers. 2012 Aug;17(5):455-62. doi: 10.3109/1354750X.2012.685952. Epub 2012 May 17. Biomarkers. 2012. PMID: 22590985

10

Functional and biologic metrics for predicting radiation pneumonitis in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy.

Wang D, Zhu J, Sun J, Li B, Wang Z, Wei L, Yin Y, Sun H, Fu Z, Zhang X, Huo Z. Wang D, et al. Clin Transl Oncol. 2012 Dec;14(12):943-52. doi: 10.1007/s12094-012-0890-3. Epub 2012 Jul 20. Clin Transl Oncol. 2012. PMID: 22855174

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

641 results

Search Page

Filters